A t the conclusion of this CME activity, participants will be able to predict the risk of cardiogenic shock in patients with ST-elevation myocardial infarction (STEMI) using N-terminal prohormone brain natriuretic peptide (Nt pro-BNP) levels. Cardiogenic shock is the major cause of death in patients with acute myocardial infarction (1) . The incidence of cardiogenic shock among patients with STEMI has been relatively stable over the past three decades (7%-10%) with a mortality rate of 40% to 60% (2) . Once cardiogenic shock has developed, the specific therapeutic approaches are limited and, currently, none of these measures has been proven to significantly improve short-term outcome (2) (3) (4) . Therefore, identification of patients at risk for development of shock during the early hospital phase of STEMI is a high priority and useful target for novel preventive measures aimed at avoiding hemodynamic compromise (1, 2, 5) .
B-type natriuretic peptide and the Nterminal fragment of its pro-hormone (NtproBNP) might be useful in this regard because the secretion of these peptides is influenced by both pro-inflammatory cytokines and hemodynamic factors, which are major contributors for the development of shock (6) . Several recent retrospective observations have shown that patients with acute coronary syndrome with or without ST elevation are at highest risk for death or heart failure independent of time to treatment, mode of reperfusion strategy, or infarct size if they have high initial Nt-proBNP concentrations (7) (8) (9) (10) (11) (12) . Furthermore, it could be shown that plasma concentrations of NtproBNP strongly predict 30-day survival of patients with cardiogenic shock (13) . In the present study we investigated whether plasma concentrations of Nt-proBNP, determined in the acute phase of STEMI, could predict the early occurrence of cardiogenic shock during the index hospital stay, either alone or in combination with other known predictors of shock.
SUBJECTS AND METHODS

Patients and Study Protocol
The study protocol and the results of the ASSENT-4 percutaneous coronary intervention (PCI) trial have been described previously (14) . In brief, the inclusion criteria of the trial were age 18 yrs or older, symptom onset Յ6 before randomization, intention to undertake primary PCI, ST-segment elevations across multiple leads, or new left bundle branch block, respectively. Exclusion criteria were expected arrival at the catheterization laboratory Ͻ1 hr or Ͼ3 hrs after randomization and the usual contraindications to fibrinolytic therapy, as described in ASSENT-3 (15) . Patients were randomly assigned to primary PCI or to PCI facilitated by the administration of a standard bodyweight-adjusted bolus of tenecteplase (15) . The study was prematurely stopped because of significantly higher inhospital mortality in the full-dose tenecteplase before PCI group. The institutional review board of every hospital involved approved the protocol, and every patient had to provide written informed consent.
In the present retrospective analysis of these prospectively collected data, all patients were included who had no signs of shock and had available plasma samples for determination of Nt-proBNP determination at randomization. Samples were collected in plastic tubes, frozen at Ϫ20°C, and batch-shipped after collection of the last sample. NT-proBNP concentrations were measured in a clinical core laboratory (University Hospitals Leuven, Leuven, Belgium) using an automated clinical chemistry analyzer coefficient of variation is 3.38% at 134.5 pg/mL and 2.76% at 5087.5 pg/mL). Thrombolysis in myocardial infarction flow perfusion grades before and after the index PCI were analyzed by investigators of the AngioCore Laboratory (University Hospital Gasthuisberg, Leuven, Belgium) who were blinded for the Nt-proBNP results, treatment, and the clinical course of the patients. Overall, 636 patients were excluded because of lack of available blood samples and 22 patients had signs or symptoms of shock at randomization.
Global Utilization of Streptikonase and TissuePlasminogen Activator for Occluded Coronary Arteries Score
The Global Utilization of Streptikonase and Tissue-Plasminogen Activator for Occluded Objective: Cardiogenic shock is a major cause of death in ST elevation myocardial infarction. We investigated whether determination of B-type natriuretic peptide and the N-terminal fragment of its pro-hormone in the acute phase of ST elevation myocardial infarction could identify patients prone to development of cardiogenic shock.
Design: Retrospective analysis of a multicenter, randomized open-label trial (ASSENT-4 PCI; ClinicalTrials.gov Identifier: NCT00168792).
Methods: Plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone were determined in available stored samples of 1016 ST elevation myocardial infarction patients without signs of cardiogenic shock at randomization to primary percutaneous coronary intervention or to full-dose tenecteplase before percutaneous coronary intervention. The end point of the present analysis was in-hospital cardiogenic shock.
Interventions: None.
Measurements and Main Results:
In total, 57 (5.6%) patients had cardiogenic shock during index hospitalization. In-hospital cardiogenic shock increased precipitously with higher baseline concentrations of plasma B-type natriuretic peptide and the Nterminal fragment of its pro-hormone (B-type natriuretic peptide and the N-terminal fragment of its pro-hormone <67 pg/mL: 1.9%; 68 -1482 pg/mL: 5.9%; >1482 pg/mL: 14.9%; p < .001).
Higher B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations were predictors of in-hospital shock, especially among those patients with relatively low clinical risk (no requirement of inotropic support before angiography, systolic blood pressure >100 mm Hg, heart rate <100 bpm, Coronary Arteries (GUSTO) score for prediction of cardiogenic shock in patients with acute STEMI was calculated for each patient as described previously (16) . Because all patients in the full-dose tenecteplase before PCI arm of the ASSENT-4 PCI trial received tenecteplase before coronary angiography and patients of the primary PCI arm received no thrombolysis, the "treatment" variable of the original score was not used for determination of these individual scores. For the purpose of analysis, the GUSTO score was analyzed in quintiles (Q1, Q2, Q3, Q4, and Q5).
Study End Point
The end point of the present analysis was the occurrence of in-hospital cardiogenic shock defined as systolic blood pressure Ͻ90 mm Hg for at least 30 mins (or the need for supportive therapy to maintain a systolic blood pressure of Ͼ90 mm Hg) in the presence of a heart rate of Ͼ60 bpm and in association with signs of hypoperfusion (cool extremities or urinary output of Ͻ30 mL/hr or mental confusion, or both) or by a cardiac index of Ͻ2.2 L/min/m 2 in the presence of a pulmonary capillary wedge pressure of Ͼ15 mm Hg. All cardiogenic shock end points were blindly adjudicated by an independent Clinical Event Committee.
Statistical Analysis
Continuous variables are described by mean Ϯ SD unless depicted otherwise. Relationships between continuous variables were determined by Spearman's rank correlation test and linear regression analyses. Categorical variables and event rates were compared using the Pearson chi-square test, whereas the Student's t test or the Mann-Whitney U test were used if appropriate to compare continuous variables.
Chi-square automatic interaction detectors algorithm of classification-tree analysis (17) (18) (19) was used to define optimal cut-off levels of Nt-proBNP concentrations to predict in-hospital cardiogenic shock. Using two cutoff points, three risk groups were defined (chisquare ϭ 21.98; p Ͻ .001): patients with NtproBNP concentrations Յ67 pg/mL (n ϭ 309; reference category); patients with Nt-proBNP between 68 and 1482 pg/mL (n ϭ 606); and patients with Nt-proBNP Ͼ1482 pg/mL (n ϭ 101). We used these cut-offs of Nt-proBNP in further analyses.
Univariate Cox regression analysis was performed to identify significant independent predictors of outcome. Predictors significant at the 0.2 level were included in the multivariate analysis with a backward selection method. The following variables were tested in univariate analyses: study arm, age, gender, history of diabetes mellitus, hypertension, myocardial infarction, PCI, coronary artery bypass grafting and congestive heart failure, anterior wall location of STEMI, systolic and diastolic blood pressures and heart rate at admission, Killip classification, time from symptom onset to start of treatment, as well as creatinine kinase, creatinine-myocardial band, hemoglobin, hematocrit, erythrocytes, and white blood cell count, and Nt-proBNP concentrations at randomization. Patients who died without having cardiogenic shock were censored for the occurrence of shock. The proportional hazards assumption was confirmed by the Schoenfeld residual test.
All statistical tests were two-tailed and statistical significance was accepted if for p Ͻ 0.05. The Software Package for Social Sciences (SPSS, Chicago, IL) was used for all statistical calculations.
RESULTS
Baseline Characteristics
One-thousand sixteen patients were included in the present analysis. All these patients had Nt-proBNP determination at randomization and had no clinical signs of cardiogenic shock at randomization (Killip Class Ͻ4). Patients who were included in the present analysis and those who were not showed similar clinical characteristics, with the exception of 
Rates of in-hospital cardiogenic shock were comparable between the groups of patients with or without Nt-proBNP determination at randomization (5.6% vs. 4.7%; p ϭ .407).
The clinical characteristics of the patients included are listed in Table 1 . In total, 57 patients had cardiogenic shock after randomization. These patients were significantly older, more frequently female, had lower systolic and diastolic blood pressures, and more frequently had a heart rate Ͼ100 bpm at admission, higher GUSTO score, and significantly higher prevalence of anterior wall myocardial infarction. The rate of previous myocardial infarction and congestive heart failure were also significantly different. The extent of myocardial infarction measured by the plasma levels of cardiac enzymes was not significantly different between patients with or without cardiogenic shock during index hospital stay. Patients who had cardiogenic shock had slightly lower erythrocyte count and hemoglobin levels and significantly higher concentrations of Nt-proBNP at randomization. With respect to therapy before coronary interventions, only the rates of positive inotropic support and intravenous diuretic therapy differed significantly (Table 2) . Figure 1 shows the rates of in-hospital shock according to the groups of baseline Nt-proBNP concentrations defined by classification-tree analysis. The incidence of shock increased significantly with increasing plasma concentrations of NtproBNP (p Ͻ .001). Figure 2 shows the rates of in-hospital shock according to the quintiles of the GUSTO score. The incidence of shock increased significantly with increasing GUSTO score (p Ͻ .001).
Survival Analysis
To test the accuracy of early plasma concentrations of Nt-proBNP to predict the development of shock after randomization, we performed Cox regression analysis. The significant predictive value of increasing Nt-proBNP concentrations showed no significant interaction with clinically relevant subgroups, including the study treatment arms (Fig. 3) .
Furthermore, in the group of patients with no need of inotropic support or intravenous diuretic therapy before angiography (n ϭ 955), the association of elevated Nt-proBNP concentrations with cardiogenic shock was also highly significant (HR, 2.72; 95% CI, 1.58 -4.66; p Ͻ .001). Patients who had cardiogenic shock during hospital stay had a substantially higher mortality rate at 90 days than those patients without shock (Table 1) . To investigate whether the relationship between increased Nt-proBNP concentrations was influenced by its strong association with mortality (HR, 1.08; 95% CI, 1.051-1.114; p Ͻ .001), we analyzed the predictive value of NtproBNP when restricted to only those patients who were alive at 90 days (n ϭ 968; in-hospital cardiogenic shock n ϭ 27). Even within this group increasing concentrations of Nt-proBNP were strongly related to increased risk of cardiogenic shock (HR,1.107; 95% CI, 1.007-1.218; p ϭ .036).
The results of the univariate Cox regression analyses are listed in Table 3 . In multivariate analysis, plasma Nt-proBNP concentrations remained significantly associated with in-hospital cardiogenic shock in addition to age older than 65 yrs, systolic blood pressure Ͻ100 mm Hg, anterior wall myocardial infarction, and Killip classification.
The GUSTO score was also highly significantly associated with the development of shock both as a continuous ( 
DISCUSSION
In the present study, we provide several novel findings that might significantly improve the prediction of cardiogenic shock in patients with acute STEMI. First, early elevation of plasma Nt-proBNP concentrations are strongly associated with development of shock despite TIMI 3 flow after coronary intervention in patients treated with or without fibrinolytic agents before PCI. Second, determination of plasma Nt-proBNP in the acute phase of STEMI significantly improves the prediction of cardiogenic shock, especially among those patients who are at low risk according to clinical parameters. Third, prediction of shock by plasma Nt-proBNP concentrations was similar among patients with shorter or longer time delay between onset of symptoms and start of treatment.
Which Patients Are at Risk for Cardiogenic Shock After STEMI?
Short-term survival of STEMI patients in cardiogenic shock is highly impaired (40%-60%) despite early coronary reperfusion (1). Once hemodynamic deterioration attributable to left ventricular pump failure developed, specific therapeutic measures are limited and are restricted to the administration of catecholamines and the use of intra-aortic balloon counterpulsation (4, 20) . Therefore, early identification of STEMI patients who are at risk for cardiogenic shock is of major clinical importance to initiate early preventive measures that might prevent hemodynamic deterioration.
According to previous data from large clinical trials and registries, predictors of cardiogenic shock are older age, diabetes, history of peripheral vascular disease, previous angina, myocardial infarction or coronary intervention (either PCI or cor- *Compared with N-terminal fragment of its pro-hormone cut-off of Յ67 pg/mL. Variables with bold letters are significant. In multivariate analysis, hazard ratio and p describe the result at which the variable was removed from the model. onary artery bypass graft), multivessel disease, and impaired left ventricular function (5, 16) . With respect to clinical variables at presentation, large anterior myocardial infarction, low systolic blood pressure, higher heart rate (Ͼ100 bpm), and signs of pulmonary congestion (Killip Ͼ1) are considered as high-risk characteristics (1, 2) . Also in the present study, these clinical variables were significant predictors of shock. More importantly, we were able to demonstrate that patients at low risk for shock (systolic blood pressure Ͼ100 mm Hg, heart rate Ͻ100 bpm, no signs of pulmonary congestion, no inotropic support) were at two-fold to three-fold higher risk of shock if the Nt-proBNP concentration was highly elevated at randomization.
Using the large GUSTO I and III database, Hasdai et al (16) developed and validated a clinical score for prediction of shock in patients with STEMI treated with thrombolysis. This risk score incorporates several variables from the medical history and physical examination. As expected, the risk of shock increased significantly with higher GUSTO score, and this association was significant in both treatment arms of the ASSENT-4 PCI trial. These data confirm previous observations and extends them by establishing the independent predictive power of the GUSTO score of the reperfusion strategy used.
More importantly, however, in the present study we could show that patients at low clinical risk according to the GUSTO score (Յ122) had significantly higher risk of shock, with higher plasma Nt-proBNP concentrations at admission. Thus, our results suggest that a combination of available clinical scores and plasma Nt-proBNP concentrations at admission might improve identification of STEMI patients at high-risk for inhospital shock.
The majority of shock observed in the ASSENT-4 PCI trial took place after coronary intervention and only a minority of shock patients presented to the hospital with clinical signs suggestive of hemodynamic compromise. In the present study, we could show that among patients with TIMI 3 flow after coronary intervention, high Nt-proBNP concentrations before angiography were significantly associated with higher risk of shock. The pathophysiological mechanisms behind this association of Nt-proBNP increase with the subsequent development of cardiogenic shock despite successful myocardial reperfusion are not known at present and are speculative. Expression and secretion of B-type natriuretic peptides are enhanced by myocardial ischemia, and recent data suggest that Nt-proBNP increases with longer total ischemia in patients with STEMI (21) . Furthermore, Nt-proBNP concentrations increase with older age and are significantly higher in patients with kidney dysfunction and/or impaired ventricular function. Thus, elevated Nt-proBNP concentrations at presentation with STEMI might reflect longer myocardial ischemia and/or represent a high-risk profile (presence of left ventricular and/or renal failure), which usually is not included in clinical shock scores. Interestingly, in the present study, plasma Nt-proBNP concentrations were significant predictors of cardiogenic shock independent of baseline clinical characteristics. Furthermore, the predictive power of Nt-proBNP elevation was even stronger among those individuals who were treated within 3 hrs after the onset of ischemic symptoms.
It is well-established that plasma NtproBNP concentrations are substantially higher in individuals who have dyspnea secondary to left ventricular failure as compared to those patients with other causes of dyspnea (22) . Thus, elevated Nt-proBNP concentrations early in the course of myocardial infarction may reflect pulmonary congestion attributable to left ventricular dysfunction induced by the acute ischemic burden. However, in the present study, we provide evidence that even patients without clinical signs of pulmonary congestion (Killip class I) or volume overload were at significantly higher risk for shock when Nt-proBNP was highly elevated at randomization.
Reperfusion injury, microvascular dysfunction, and distal embolization are associated with higher rates of adverse events, including cardiogenic shock (23). Higher preprocedural Nt-proBNP concentrations already have been shown to be related to no-reflow after primary PCI (24) . However, in the present study, the risk of shock associated with higher Nt-proBNP concentrations was substantial even after TIMI 3 flow after PCI and in the absence of visible distal embolization. The possible effects of microvascular dysfunction and reperfusion injury in patients with STEMI and high concentrations of natriuretic peptides should be established in further clinical studies and preclinical models of myocardial infarction.
BNP has natriuretic, diuretic, and vasodilatory effects and thereby protects the heart from volume overload and the development and progression of heart failure (25) . Excessive vasodilatation and volume loss in the setting of acute myocardial infarction, however, might contribute to peripheral hypoperfusion and reduce cardiac performance (26, 27) . Furthermore, BNP has negative inotropic effects and might adversely affect cardiac contractility through inhibition of the expression of sarcoplasmic reticulum Ca 2ϩ ATPase (28 -30) . Excessive expression of BNP in acute myocardial infarction could thereby counteract the beneficial effects of a successful coronary revascularization and could actively contribute to the development of shock.
Our data are hypothesis-finding, and the role and clinical usefulness of very high plasma concentrations of B-type natriuretic peptides in patients with acute myocardial infarction should be clarified by future studies. Nevertheless, similar to patients with "conventional" high-risk profiles, i.e., the elderly, those with low systolic blood pressure, increased heart rate, signs of pulmonary congestion at admission, and patients with STEMI and highly elevated Nt-proBNP at admission are at high risk for shock and should be managed with special attention.
Limitations
This study has several limitations. Although the rate of cardiogenic shock (5.7%) in this subanalysis of the ASSENT-4 PCI trial and the outcome of patients with cardiogenic shock (51% mortality rate) are comparable to recently published data (4, 31) , the number of events in our study is relatively low. Because of the low number of shocks and the high number of possible predictors, we had to reduce the full model. For this purpose, we used a backward elimination procedure using all variables that were significant at the 0.2 level in univariate analyses. Because this procedure can yield unreliable results, the present study should be prospectively validated on a larger database.
Not all patients randomized in the original ASSENT-4 PCI trial had available samples for the present analysis because some sites did not have the capability to collect, prepare, or store the samples properly for later analyses. In addition, many patients had to be transferred immediately after inclusion to the study to another acute care
